

Product Licence Number	Company Name	Product Name	Active Ingredients	Indications	Date of Authorisation
18467/0002 (continued)	Cenes Limited			especially for breast cancer since cyclizine does not elevate prolactin levels. Valoid may be value in relieving vomiting and attacks of vertigo associated with Meniere's disease and other forms of vestibular disturbance when the oral route cannot be used. Valoid Injection, by the intravenous route, is also indicated pre-operatively in patients undergoing emergency surgery in order to reduce the hazard of regurgitation and aspiration of gastric contents during induction of general anaesthesia.	
18467/0003	Cenes Limited	Diconal Tablets	Cyclizine Hydrochloride 30.000 mg Dipipanone Hydrochloride 10.000 mg	Prescription Only Medicine For the management of moderate to severe pain in medical and surgical conditions in which morphine may be indicated. Cyclizine is effective in preventing nausea and vomiting associated with the administration of narcotic analgesics.	1st January 2001
18467/0004	Cenes Limited	Cyclimorph 10 Injection	Cyclizine 39.010 mg Morphine Tartrate 10.000 mg	Prescription Only Medicine For the relief of moderate to severe pain in all suitable medical and surgical conditions and in which reduction of the nausea and vomiting associated with the administration of morphine is required.	1st January, 2001
18467/0005	Cenes Limited	Cyclimorph 15 Injection	Cyclizine 3.901 mg Morphine Tartrate 15.000 mg	Prescription Only Medicine Same as in PL 18467/0004.	1st January, 2001
18532/0001	Evans Vaccines Limited	Fluvirin® [Inactivated Influenza Vaccine (Surface Antigen) EP]	A/New Caledonia/20/99 IVR-116 (H1N1) 15.000 mcg Influenza Virus B/Beijing/184/93-Like 15.000 mcg (B/Yamanashi/166/98) Virus Influenza A/Panama/2007/99 15.000 mcg Resvir-17 (H3N2)	Prescription Only Medicine Prophylaxis of influenza, especially in those who run an increased risk of associated complications.	1st January, 2001
18532/0002	Evans Vaccines Limited	Inactivated Influenza Vaccine (Surface Antigen) Ph Eur	Influenza Virus B/Beijing/184/93-Like 30.000 ug/ml (B/Yamanashi/166/98) Virus Influenza A/Moscow/10/99 (H3N2) 30.000 ug/ml Like Virus Influenza A/New Caledonia/20/99 30.000 ug/ml Ivr-116 (H1N1)	Prescription Only Medicine Same as in PL 18532/0001	1st January, 2001
18532/0003	Evans Vaccines Limited	Arilvax, Yellow Fever Vaccine, Live BP	Virus Yellow Fever (17D Strain Live) 3.700 Igpfu	Prescription Only Medicine For active immunisation of residents in yellow fever endemic areas.	1st January, 2001
18532/0009	Evans Vaccines Limited	BCG Vaccine Intradermal	BCG Copenhagen Sub-Strain 1077 26000000.000 vu/ml	Prescription Only Medicine For active immunisation against tuberculosis. Vaccinated persons normally become Mantoux-positive after eight weeks, but sometimes up to 14 weeks are needed.	1st January, 2001
18532/0010	Evans Vaccines Limited	BCG Vaccine Percutaneous	BCG Copenhagen Sub-Strain 1077 25000000.000 vu/ml	Prescription Only Medicine For active immunisation against tuberculosis in neonates, infants and very young children only. Vaccinated persons normally become Mantoux-positive after eight weeks, but sometimes up to 14 weeks are needed.	1st January, 2001
18532/0011	Evans Vaccines Limited	BCG Vaccine Intradermal Isoniazid Resistant	BCG Isoniazid-Resistant Sub-Strain 26000000.000 vu/ml	Prescription Only Medicine For active immunisation against tuberculosis in tuberculous contacts while they are receiving prophylactic treatment with isoniazid. It is well established that BCG vaccination of contacts confers protection against tuberculosis and it is especially useful in this respect for newborn infants of tuberculous mothers or infants born into tuberculous households. However, under such circumstances segregation is necessary until Mantoux testing has shown conversion. This undesirable segregation period of a few weeks can be abolished by giving isoniazid to the infant from birth, but the adoption of this procedure suffers from the disadvantage that concurrent administration of isoniazid interferes with the response to normal BCG vaccine. This can be avoided by the use of an isoniazid resistant BCG vaccine, when administration of isoniazid need only continue until the post-BCG tuberculin test becomes positive.	1st January, 2001